gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GHHealthcareMedical Labs

Guardant Health, Inc. Common Stock (GH)

$168.58−3.67%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$175.00▲ 76.91% in range
Nov 3, 2025Low $78.60 · High $187.22Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Guardant Health closed at $168.58 on Nov 4, down 3.67%, 10.0% below its 52-week closing high. Volume of 2.2M shares was 1.29× its 20-day average (above normal).

Split-adjusted performance: -1.2% over one month, +82.7% over six months, +70.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $334.98M, up 44.3% from a year earlier, with a net margin of -35.9%.

Short interest was 11.7M shares at the Oct 15 settlement, down 2.1% from the prior report (9.2% of float, 6.7 days to cover).

Market cap$22.62B134.2M shares
Revenue · quarter$335.0M+44.3% YoY
Diluted EPS$-0.90—
P/E · TTM—P/S 19.1×
Net margin-35.9%Gross 65.4%
Dividend yieldNone
52-week range78.60 – 187.22−10.0% from high
Volume2.2M1.29× 20-day avg
Volatility · 60d45.0%Annualised
Short % of float9.2%6.7 days to cover
Net cash-$449.5MCash $1.05B
Next earnings—Not scheduled
Split-adjusted performance
1W −7.7%1M −1.2%3M +7.0%6M +82.7%YTD +65.0%1Y +70.4%3Y +565.5%5Y +50.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum82
Revenue growth89
Net margin24
Value (low P/E)—
Size87

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short11.7M−2.1% vs prior
Days to cover6.7Settled Oct 15
% of float9.2%
Short vol. 10d48.9%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GHGuardant Health$168.58−3.67%+82.7%+44.3%−35.9%—$22.62B
DGXQuest Diagnostics$255.68+3.49%+35.2%+10.0%10.0%25.1$28.22BCompare
LHLabcorp Holdings$367.79+3.92%+43.1%+6.9%6.9%29.7$29.86BCompare
CAICaris Life Sciences$33.22+1.13%+73.7%+45.4%−0.2%89.3$9.39BCompare
NTRANatera$391.03+0.62%+81.8%+37.7%−8.9%—$56.36BCompare
GRALGRAIL$143.66+3.03%+128.9%+25.7%−246.7%—$6.42BCompare
RDNTRadNet$80.26+9.67%+36.9%+25.0%1.2%—$6.32BCompare
BLLNBillionToOne$113.89+3.11%+39.9%—7.4%—$5.37BCompare
CDNACareDx$85.86−2.95%+309.8%+39.3%13.8%35.1$4.51BCompare

News about Guardant Health

All news →
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · 6d ago▲ PositiveGuardant Health Secures FDA Approval For Expanded Liquid Biopsy TestBenzinga · May 20, 2026▲ Positive

Quick answers

What does Guardant Health do?
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening.
What is GH's market cap?
$22.62B, based on the Nov 4 close of $168.58.
Does Guardant Health pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GH is sold short?
11.7M shares, 9.2% of float, as of Oct 15, 2026.
What sector is GH in?
Healthcare, in the Medical Labs industry.

About Guardant Health

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

HQ: Palo Alto, CA2,506 employeesListed Oct 4, 2018guardanthealth.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology